July 6, 2005 — Nanosphere Inc., a Northbrook, Ill., nanotechnology-based life sciences company, announced that Gregory Shipp has joined the company as its first vice president of medical affairs.
Shipp brings experience in medical, clinical and regulatory affairs management. The appointment comes as Nanosphere prepares to introduce Verigene, a system to enable ultra-sensitive detection of DNA, RNA and proteins on a single platform.
Most recently, Shipp was medical director and chief medical officer for i-STAT Corp., an Abbott Point-of-Care division, where he managed relations with laboratory medical directors and clinical physicians domestically and abroad. He also created awareness of point-of-care testing benefits through the development of post-market clinical studies.
Prior to i-STAT, Shipp was clinical affairs director for Boston Scientific Medi-tech, where he managed the clinical evaluation of an implantable abdominal aortic stent-graft across 26 sites. Before joining Boston Scientific, he was senior medical officer for Bio-Reg Associates. There, he led clinical studies of medical devices in the areas of ophthalmology, plastic surgery, urology and bone physiology.